Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Related records

Trials (18)

• A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
• A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
• A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
• A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
• A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
• A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
• A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
• A Study of RPL554 in Patients With Cystic Fibrosis
• Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
• Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
• Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
• Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
• Effect of Ensifentrine Treatment on CAT Score
• SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects
• Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler
• Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
• The Effects of RPL554 in Addition to Tiotropium in COPD Patients
• The Effects of RPL554 on Top of Standard COPD Reliever Medications